Pasar al contenido principal

LA RED MYC-MNT: NUEVAS INTERACCIONES Y SU IMPACTO EN NEOPLASIAS HEMATOLOGICAS

PID2020-115903GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CANTABRIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MYC directly transactivates CR2/CD21, the receptor of the Epstein-Barr virus, enhancing the viral infection of Burkitt lymphoma cells

  • Molina Hoyo, Ester
  • García-Gutiérrez, Lucía
  • Junco, Vanessa
  • Perez-Olivares, Mercedes
  • Yébenes, Virginia G. de
  • Blanco, Rosa
  • Quevedo, Laura
  • Acosta, Juan C.
  • Marín, Ana V.
  • Ulgiati, Daniela
  • Merino, Ramón
  • Delgado, M. Dolores
  • Varela, Ignacio
  • Regueiro, José R.
  • Moreno de Alborán, Ignacio
  • Ramiro, Almudena R.
  • León, Javier
MYC is an oncogenic transcription factor dysregulated in about half of total human tumors. While transcriptomic studies reveal more than 1000 genes regulated by MYC, a much smaller fraction of genes is directly transactivated by MYC. Virtually all Burkitt lymphoma (BL) carry chromosomal translocations involving MYC oncogene. Most endemic BL and a fraction of sporadic BL are associated with Epstein–Barr virus (EBV) infection. The currently accepted mechanism is that EBV is the BL-causing agent inducing MYC translocation. Herein we show that the EBV receptor, CR2 (also called CD21), is a direct MYC target gene. This is based on several pieces of evidence: MYC induces CR2 expression in both proliferating and arrested cells and in the absence of protein synthesis, binds the CR2 promoter and transactivates CR2 in an E-box-dependent manner. Moreover, using mice with conditional MYC ablation we show that MYC induces CR2 in primary B cells. Importantly, modulation of MYC levels directly correlates with EBV’s ability of infection in BL cells. Altogether, in contrast to the widely accepted hypothesis for the correlation between EBV and BL, we propose an alternative hypothesis in which MYC dysregulation could be the first event leading to the subsequent EBV infection., The work was supported by grants PID2020-115903GB-100 to JL and MDD, RTI2018-095673-B-I00 to JRR, PID2019-107551RB-I00 to VG-Y, PID2020-119567RB-I00 to RM, PID2020-117539GB-I00 to IV and PID2019-106773RB-I00 to ARR, all funded by MCIN/AEI/10.13039/501100011033/, Spanish Government, and by “FEDER, Una manera de hacer Europa”, European Union, and by La Caixa HR17-0244 grant to AR. LQ and VJ were recipients of F.P.U. program and Universidad de Cantabria fellowships, respectively. LG-G was a fellow of the Maria Zambrano program, Spanish Government.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ERK2 stimulates MYC transcription by anchoring CDK9 to the MYC promoter in a kinase activity-independent manner

  • Agudo-Ibáñez, Lorena
  • Morante, Marta
  • García-Gutiérrez, Lucía
  • Quintanilla, Andrea
  • Rodríguez, Javier M.
  • Muñoz Terol, Alberto
  • León, Javier
  • Crespo, Piero
The transcription factor MYC regulates cell proliferation, transformation, and survival in response to growth factor signaling that is mediated in part by the kinase activity of ERK2. Because ERK2 can also bind to DNA to modify gene expression, we investigated whether it more directly regulates MYC transcription. We identified ERK2 binding sites in the MYC promoter and detected ERK2 at the promoter in various serum-stimulated cell types. Expression of nuclear-localized ERK2 constructs in serum-starved cells revealed that ERK2 in the nucleus—regardless of its kinase activity—increased MYC mRNA expression and MYC protein abundance. ERK2 bound to the promoter through its amino-terminal insert domain and to the cyclin-dependent kinase CDK9 (which activates RNA polymerase II) through its carboxyl-terminal conserved docking domain. Both interactions were essential for ERK2-induced MYC expression, and depleting ERK impaired CDK9 occupancy and RNA polymerase II progression at the MYC promoter. Artificially tethering CDK9 to the MYC promoter by fusing it to the ERK2 insert domain was sufficient to stimulate MYC expression in serum-starved cells. Our findings demonstrate a role for ERK2 at the MYC promoter acting as a kinase-independent anchor for the recruitment of CDK9 to promote MYC expression., The work was supported by grants RTI2018-096658B-100 to P.C., PID2020-115903GB-100 to J.L., and PID2019-104867RB-100 to A.M. from the Spanish Ministry of Science (MCIN/AEI/10.13039/501100011033/, Spanish Government and FEDER); a grant from Asociación Española Contra el Cancer (AECC; GCB141423113) to P.C.; and a grant from CIBERONC from (CB16/12/00273) from Instituto de Salud Carlos III-FEDER to P.C. and A.M.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Functional Interaction Between Epstein–Barr Virus and MYC in the Pathogenesis of Burkitt Lymphoma

  • Solares, Sandra
  • León, Javier
  • García-Gutiérrez, Lucía
The Epstein–Barr virus (EBV) is associated with a wide range of diseases, malignant and non-malignant. EBV was, in fact, the first virus described with cell transformation capacity, discovered by Epstein in 1964 in lymphoma samples from African children. Since then, EBV has been associated with several human tumors including nasopharyngeal carcinoma, gastric carcinoma, T-cell lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma, and Burkitt lymphoma among others. The molecular hallmark of Burkitt lymphoma (BL) is a chromosomal translocation that involves the MYC gene and immunoglobulin loci, resulting in the deregulated expression of MYC, an oncogenic transcription factor that appears deregulated in about half of human tumors. The role of MYC in lymphoma is well established, as MYC overexpression drives B cell proliferation through multiple mechanisms, foremost, the stimulation of the cell cycle. Indeed, MYC is found overexpressed or deregulated in several non-Hodgkin lymphomas. Most endemic and many sporadic BLs are associated with EBV infection. While some mechanisms by which EBV can contribute to BL have been reported, the mechanism that links MYC translocation and EBV infection in BL is still under debate. Here, we review the main EBV-associated diseases, with a special focus on BL, and we discuss the interaction of EBV and MYC translocation during B cell malignant transformation in BL., This research was funded by MICIU/AEI/10.13039/501100011033, grant number PID2020-115903GB-100 to J.L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CTCF Regulates Erythroid Differentiation Through Control of Core Erythroid Transcription Factors

  • García-Gaipo, Lorena
  • Junco, Vanessa
  • García-Gutiérrez, Lucía
  • Torrano, Verónica
  • Blanco, Rosa
  • Wiesinger, Alexandra
  • Pradeep, Rujula
  • Arroyo, Jose Luis
  • Batlle-López, Ana
  • León, Javier
  • Rosa-Garrido, Manuel
  • Delgado, M. Dolores
Erythropoiesis is tightly regulated by lineage-specific transcription factors that govern erythroid commitment, proliferation, and differentiation. A core erythroid transcriptional network, together with non-DNA-binding cofactors, occupies regulatory regions of genes essential for erythroid development. This process is further shaped by epigenetic mechanisms, including histone post-translational modifications and long-range chromatin interactions. CCCTC-binding factor (CTCF) is a multifunctional regulator with a central role in three-dimensional chromatin organization. Although CTCF has been implicated in hematopoietic differentiation and leukemogenesis, its specific function in erythropoiesis remains poorly defined. Here, we investigated the role of CTCF during erythroid differentiation using two complementary models: pluripotent K562 leukemia cells and primary human CD34+ hematopoietic stem/progenitor cells, each induced toward the erythroid lineage by distinct stimuli. In both systems, CTCF silencing impaired erythroid differentiation by repression of key erythroid transcription factor genes, including LMO2, KLF1, MYB, and ETS1. This repression was associated with enrichment of repressive histone marks at CTCF-binding sites within their regulatory regions. Moreover, CTCF cooperated with cohesin to establish and stabilize long-range chromatin interactions at these loci. These results provide new insight into how CTCF-dependent chromatin regulation contributes to normal erythroid development and suggest that perturbation of this regulatory axis may have implications for hematopoietic disorders and malignancies., This research was funded by MCIN/AEI/10.13039/501100011033/, Spanish Government, and by “FEDER, Una manera de hacer Europa”, European Union. Grants SAF2017-88026-R and PID2020-115903GB-100 to J.L. and M.D.D., Peer reviewed